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Supp1ementary 1: Effect of increasing doses of MK801 on 5-CSRTT performance – cohort 1 
Results 
The effects of MK801 on 5-CSRTT performance, 10 minutes after administration, are shown 
in Fig. S1. MK801 significantly increased % premature responding (F2,22=4.0, p<0.05, X
2
=30, 
GG Ɛ=0.50) compared with vehicle-treated rats. This effect was significant at 0.06 mg/kg 
(p<0.05), increasing % premature responding from 6.08±1.3 to 50.1±14.7 %. However, the 
individual response to MK801 was highly variable; the range of premature responses elicited 
by 0.06 mg/kg varied between 3 and 140 %.  
Although there was an overall increase in omissions (main effect of dose, F1,14=52.5, p<0.001, 
X
2=50, GG Ɛ=0.32) and decrease in accuracy (main effect of dose, F2.20=8.4, p<0.01, X
2
=29, 
GG Ɛ=0.45), these effects were only evident following 0.1 mg/kg MK801 administration 
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(p<0.001 and p<0.05 respectively). Indeed, 0.06 mg/kg MK801 had no effect on any other 
behavioural variable apart from magazine latencies (F1,15=6.6, p<0.05, X
2=39, GG Ɛ=0.37) 
where MK801 produced a significant dose-dependent decrease in the latency to collect food 
reward at 0.015, 0.03 and 0.06 mg/kg (p<0.001) (data not shown). 
Based on these results, a dose of 0.06 mg/kg MK801 was selected for MK801 studies in 
cohort 1. This dose provided a selective increase in premature responding, without having any 
substantial effect on other behavioural variables.  
 
 
Fig. S1: Dose-dependent effects of MK801 (0-0.1 mg/kg) on 5-CSRTT performance (n=12); 
(a) % premature responses, (b) % omissions, (c) % accuracy, (d) correct response latency 
(sec). Bars represent means ± SEM. Repeated measures one-way ANOVA, Dunnett’s post 
hoc test * p<0.05, *** p<0.001 versus vehicle control. Premature responding data were 
transformed (SQRT (% premature + 1) to satisfy the requirement of homogeneity of variance. 
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Supplementary 2: Effect of increasing doses of MK801 on 5-CSRTT performance – cohort 2 
Results 
The effects of MK801 on 5-CSRTT performance, 10 minutes after administration, are shown 
in Fig. S2. MK801 significantly and dose-dependently increased premature responding 
(F2,27=4.7, p<0.05), reaching significance at 0.06 mg/kg only (p<0.01). No other task 
parameter was affected by MK801 at any dose apart from a significant increase in speed to 
respond correctly (F2,27=3.4, p<0.05), following 0.03 mg/kg MK801 (p<0.05).  
 
Based on these data, a dose of 0.03 mg/kg was selected for MK801 studies in cohort 2. 
Although non-significant, a robust, selective increase in premature responding was observed 
following 0.03 mg/kg MK801. Furthermore, it was apparent that the effect of 0.06 mg/kg 
MK801 on premature responding was large and variable between different subjects. 
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Fig. S2: Dose-dependent effects of MK801 (0-0.06 mg/kg) on 5-CSRTT performance (n=30); 
(a) % premature responses, (b) % omissions, (c) % accuracy, (d) correct response latency 
(sec). Bars represent means ± SEM. One-way ANOVA, Dunnett’s post hoc test. * p<0.05, ** 
p<0.01 versus vehicle control.  
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Supplementary 3: Pharmacokinetic properties of RO4917523 and ADX47273 
Table S1 
RO4917523  
Molecular weight: 325.8 
Dose: 17.9 µM/kg (5.8 mg/kg), p.o 
 
 
Mean (n=3) 
Cmax  [nM] 3740 
Tmax [h] 2.0 
MRT [h] 7 
ADX47273  
Molecular weight: 369.4 
Dose: 271 µM/kg (100 mg/kg) p.o 
 
 
Mean (n=3) 
Cmax  [nM] 5510 
Tmax [h] 1.33 
MRT [h] 6.6 
 
Table S1: Pharmacokinetic properties of RO4917523 and ADX47273 in male Wistar rats, 
following oral administration of 5.8 mg/kg RO4917523 or 100 mg/kg ADX47273; maximal 
plasma concentration (Cmax), time taken to reach maximal plasma concentration (Tmax) and 
mean residence time (MRT) indicated (n=3 per group).  
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Supplementary 4: Plasma exposures of RO4917523, MTEP and ADX47273  
Table S2 
 
 
 
 
 
 
 
 
 
 
 
 
 
* Below detectable range; **n=1 (two samples below detectable range) 
 
Table S2: Mean plasma concentrations of RO4917523 (0.03 – 1 mg/kg, p.o, at 2 hours 15 
minutes), MTEP (1 – 30 mg/kg, i.p, at 30 minutes) and ADX47273 (80 – 100 mg/kg, p.o, at 1 
hr 45 minutes) post administration, in male Lister hooded rats.  Time points based on plasma 
exposures mid-task (i.e. 15 minutes into task). 
 
 
 
 
 
RO4917523  
(mg/kg), p.o; 
2 hrs 15 mins 
n=3 per group 
Mean Plasma 
Concentration 
(nM) 
0.03 n/a* 
0.1 25±0** 
0.3 71.2±25.5 
1 152.7±7.8 
MTEP  
(mg/kg), i.p;  
30 mins;  
n=3 per group 
Mean Plasma 
Concentration 
(nM) 
1 411.7±104.7 
3 2063.3±266.7 
10 11158.7±3978.5 
30 28015.3±8568.0 
ADX47273  
(mg/kg), p.o;  
1 hr 45 mins; 
n=4 per group 
Mean Plasma 
Concentration 
(nM) 
80 2235.0±210.0 
100 2550.0±326.4 
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Supplementary 5: In-vitro characterisation of allosteric mGluR5 modulation 
Material and methods 
Human embryonic kidney cells (HEK 293 cells), stably expressing human mGluR5, were 
plated out in 384-well clear-bottomed plates (50 µL of cells, approx. 10,000 cells per well) in 
DMEM 1X medium (10% FCS and 500 µg/ml Geneticin). Twenty-four hours later, the cells 
were washed with Hanks buffer (HBSS 10X (with Ca
2+
, Mg
2+
) and HEPES (1M), pH 7.4) and 
incubated with 20 µl calcium sensitive fluorescence dye (FLIPR calcium 4 assay kit – 
Molecular Devices, Sunnyvale, California), diluted in Hanks buffer, for 1 hour. In the NAM 
experiments, the cells were incubated with a range of concentrations of RO4917523 (10 µM – 
30 pM) or MTEP (10 µM – 30 pM), diluted in 1% DMSO, for 10 minutes. Intracellular 
calcium release measurements were made using a 384 fluorometric imaging plate reader 
(FLIPR) (FLIPR Tetra – Molecular Devices, Sunnyvale, California) in the presence of 30 µM 
glutamate. In the PAM experiment, a glutamate dose-response shift experiment was 
performed with ADX47273, to demonstrate the allosteric properties of the compound. 
Following incubation with calcium sensitive fluorescence dye, the cells were incubated with a 
range of concentrations of ADX47273 (3 µM – 10 nM), diluted in 1% DMSO, for 10 minutes 
and then stimulated with a range of concentrations of glutamate (0.3 mM – 1 nM).   
 
Results 
The effect of 30 µM glutamate on intracellular calcium release is shown in Fig.S5a. 
RO4917523 and MTEP concentration-dependently attenuated this response with IC50 values 
of 4.53 nM and 19.2 nM, respectively. Although these data do not confirm allosteric 
modulation, allosteric properties of the compounds can be assumed based on the structural 
properties of RO4917523 and MTEP and the structure of mGluR5 orthosteric versus allosteric 
binding sites (Doré et al., 2014; Jaeschke et al., 2015; Mølck et al., 2014). Nevertheless, these 
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data demonstrate that both RO4917523 and MTEP have clear negative modulatory effects on 
mGluR5.  
Application of glutamate to the cells produced a concentration-dependent increase in calcium 
release (EC50 6.57 µM) (Fig.S5b). The allosteric property of ADX47273 was demonstrated by 
the concentration-dependent leftward-shift of the glutamate-response curve (Fig. S5b). 
ADX47273 lowered the glutamate concentration threshold necessary for the cells to elicit a 
fluorescent response. In the presence of 3 µM ADX47273 (highest concentration tested), the 
EC50 of glutamate was 0.31 µM with a maximal shift factor of 21.2. ADX47273 had no 
intrinsic agonist activity at the maximal dose tested, evident by the absence of an upward shift 
in the dose-response function.  
 
 
 
 
 
 
Fig. S5: (a) Attenuation of the effects of 30 µM glutamate on mGluR5 activation by the 
negative allosteric modulators RO4917523 and MTEP. A range of concentrations of 
RO4917523 and MTEP were added to human mGluR5-expressing HEK 293 cells in the 
presence of 30 µM glutamate. Concentration-response curves were generated from the mean 
data of a total of three experiments. (b) ADX47273 concentration-dependently lowered the 
glutamate concentration threshold necessary to activate mGluR5. The leftward-shift of the 
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glutamate-response curve highlights the allosteric property of ADX47273. Data are means ± 
SD.  
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